Nishio M, Paz-Ares L, Reck M, Nakagawa K, et al. RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome. Clin Lung Cancer 2023;24:415-428.
PMID: 37076395